Data Supplement RIO-Europe RIO-Lipids RIO-Diabetes RIO-North America European labeling.

Slides:



Advertisements
Similar presentations
Manufacturer: Arena Pharmaceuticals FDA Approval Date: 06/27/2012
Advertisements

Chapter 6 Obesity. Chapter overview Definition Aetiology Genetic influence Prevalence Health risks Physical inactivity and obesity Exercise as therapy.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir +/- RBV in GT1 PEARL-III.
Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) +/- RBV in GT1 PEARL-III and PEARL-IV Phase 3 Treatment Naïve.
Rimonabant: New therapeutic option for managing cardiometabolic risk.
Farxiga™ - Dapagliflozin
TMC125 Safety and Tolerability: 24-week Results of the Pooled DUET-1 and -2 Trials R Haubrich, M Schechter, S Walmsley, M Peeters, M Janssens, G De Smedt.
Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir + RBV in GT1 SAPPHIRE-II.
Manufacturer: Celgene Corporation FDA Approval Date: 9/23/14
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Rury R. Holman, MB, ChB, FRCP Professor of Diabetic Medicine Director, Diabetes.
Hepatitis web study Hepatitis web study Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Phase 2b Treatment Naïve and Treatment Experienced.
Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Phase 2 Treatment Experienced Bourliere.
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.
Epanova ® - Omega-3- carboxylic acids Manufacturer: AstraZeneca FDA Approval Date: 05/2014.
Obesity M.A.Kubtan MD - FRCS M.A.Kubtan1. 2  Pulmonary Disease  Fatty Liver Disease  Orthopedic Disorders  Gallbladder Disease  Psychological Impact.
305 Study Randomised, Double Blind, Placebo Controlled Phase III Safety and Efficacy Study (8 and 12 mg OD) Conducted in Europe, Asia, North America, Australia,
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
1 The Study of Trandolapril- verapamil And insulin Resistance STAR determined whether glycaemic control was maintained to a greater degree by an RAS inhibitor/non-DHP.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP

Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257  WAVES.
Medicine used in the Treatment of Obesity
1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 3 of 4.
Copyright © 2011 Actelion Pharmaceuticals Ltd SERAPHIN: RESULTS FROM A LANDMARK STUDY.
The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Contemporary Management of Cardiometabolic Risk. A continuing epidemic: 2 of 3 US adults are overweight or obese National Health and Nutrition Examination.
A Diabetes Outcome Progression Trial
The University of Wisconsin Medical School The Center for Tobacco Research and Intervention Treating Tobacco Addiction in a Subject concerned about Weight.
Sprout Pharmaceuticals Inc. FDA Approval Date: August 18, 2015
Diabetes Prevention Program (DPP)
Journal of the American Medical Association (JAMA), 2004, 291:
Int J Clin Pract, December 2013, 67, 12,
Tresiba- insulin degludec
W24 ≥ 18 years Chronic HCV infection Genotype 1 Treatment naïve Early fibrosis to compensated cirrhosis No HBV or HIV co-infection N = 10 SOF + weight-based.
Angelo L Gaffo Kenneth G Saag Core Evidence 2009:4 25–36
for The STRADIVARIUS Investigators
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
Effects of Memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised,
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.
Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Hepatitis web study Hepatitis web study Elbasvir + Grazoprevir in GT 1 and Chronic Renal Disease C-SURFER Phase 3 Treatment Naïve and Treatment Experienced.
 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.

Multicenter, Placebo-Controlled Trial
RESULTS OF THE RIMONABANT IN OBESITY (RIO) PROGRAM AT 1 YEAR
Neal B, et al. Diabetes Care 2015;38:403–411
ARV-trial.com Switch to E/C/F/TAF GS-US Study 1.
Placebo group 5-mg rimonabant group p 20-mg rimonabant group
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
Section overview: Cardiometabolic risk reduction
Flow of Patients Through Trial
Pramlintide Therapy Part 1of 2
New Models of Care in Idiopathic Pulmonary Fibrosis
Presentation transcript:

Data Supplement RIO-Europe RIO-Lipids RIO-Diabetes RIO-North America European labeling

RIO-Europe: Study design N = 1507 BMI ≥30 kg/m 2 or >27 kg/m 2 with comorbidity* -600 kcal/day + advised to  PA Placebo Enrolled = 305 Completed = 178 Rimonabant 20 mg Enrolled = 599 Completed = 363 *Hypertension and/or dyslipidemia † Last observation carried forward Primary endpoint: Weight change from baseline † Secondary endpoints: Weight loss ≥5% and ≥10%, waist circumference, FG, fasting insulin, total-C, HDL-C, LDL-C, TG, MetS, HOMA-IR Follow-up: 1 year Van Gaal LF et al. Lancet. 2005;365:

RIO-Europe: Treatment effect on weight and waist circumference Weeks (intent-to-treat population) LOCF *P ≤ vs placebo LOCF = last observation carried forward ∆ WC (cm) PlaceboRimonabant 20 mg LOCF ∆ Body weight (kg) * *

Placebo RIO-Europe: Treatment effect on lipids Van Gaal LF et al. Lancet. 2005;365: No significant effect on LDL-C or total-C *P ≤ vs placebo Weeks (intent-to-treat population) LOCF LOCF01224 –10 – – * * ∆ HDL-C (%) ∆ TG (%) Rimonabant 20 mg

RIO-Europe: Adverse events Placebo (%) (n = 305) Rimonabant 20 mg (%) (n = 599) Nasopharyngitis Influenza Gastroenteritis Upper respiratory tract infection (URTI) Bronchitis Sinusitis Headache Dizziness Nausea Diarrhea Arthralgia Back pain Fatigue Van Gaal LF et al. Lancet. 2005;365: ≥5% incidence in any group

RIO-Lipids: Study design N = 1033 BMI kg/m 2 with untreated dyslipidemia* -600 kcal/day + advised to  physical activity Placebo Enrolled = 342 Completed = 214 Rimonabant 20 mg Enrolled = 346 Completed = 221 *TG and/or Total-C/HDL-C >4.5 (women) or >5 (men) † LOCF OGTT = oral glucose tolerance test Primary endpoint: Weight change from baseline † Secondary endpoints: HDL-C, TG, insulin, OGTT, MetS, leptin, adiponectin Follow-up: 1 year Després J-P et al. N Engl J Med. 2005;353:

RIO-Lipids: Treatment effect on weight and WC Després J-P et al. N Engl J Med. 2005;353: Intent-to-treat population ∆ Body weight (kg) Weeks 52 Placebo Rimonabant 20 mg *P < vs placebo ∆ WC (cm) * *

RIO-Lipids: Treatment effect on lipids Després J-P et al. N Engl J Med. 2005;353: Intent-to-treat population *P < vs placebo No significant effect on LDL-C and total-C PlaceboRimonabant 20 mg ∆ HDL-C (%) Weeks ∆ TG level (%) * *

RIO-Lipids: Rimonabant weight-independent effect on adiponectin Després J-P et al. N Engl J Med. 2005;353: % of adiponectin increase was independent of weight loss PlaceboRimonabant 20 mg ∆ Adiponectin level (  g/mL) –55–10≥10Weight gain Weight loss (%)

RIO-Lipids: Adverse events Placebo (%) (n = 342) Rimonabant 20 mg (%) (n = 346) Nasopharyngitis Headache Nausea Dizziness Influenza URTI Anxiety Back pain Diarrhea Gastroenteritis Insomnia Arthralgia ≥5% incidence in any group Després J-P et al. N Engl J Med. 2005;353:

RIO-Diabetes: Study design N = 1047 T2DM, BMI 27–40 kg/m 2, A1C 6.5%–10%, and FG 100–271 mg/dL -600 kcal/day + advised to  PA Placebo Enrolled = 348 Completed = 231 Rimonabant 20 mg Enrolled = 339 Completed = 229 Scheen AJ et al. Lancet. 2006;368: *LOCF Primary endpoint: Weight change from baseline* Secondary endpoints: A1C, HDL-C, TG, FG, fasting insulin, hsCRP, leptin, MetS, waist circumference, BP Follow-up: 1 year

RIO-Diabetes: Treatment effect on weight and waist circumference WeightWaist circumference P < Scheen AJ et al. Lancet. 2006;368: Δ Body weight (lb) Δ WC (in) Week Week -2 Intent-to-treat population PlaceboRimonabant 20 mg/day

Δ from baseline (%) RIO-Diabetes: Treatment effect on lipids No significant effect on LDL-C and total-C Scheen AJ et al. Lancet. 2006;368: HDL-CTriglycerides P < Δ from baseline (%) Week Week PlaceboRimonabant 20 mg

RIO-Diabetes: Treatment effect on glucose metabolism A1C Δ from baseline (%) Δ from baseline HOMA-IR P < P = 0.03 PlaceboRimonabant 20 mg Scheen AJ et al. Lancet. 2006;368:

RIO-Diabetes: Adverse events Placebo (%) (n = 348) Rimonabant 20 mg (%) (n = 339) Nausea612 Nasopharyngitis2112 Dizziness59 Arthralgia89 Headache98 Diarrhea77 Back pain77 URTI97 Vomiting26 Hypoglycemia25 Fatigue45 Anxiety35 ≥5% incidence in any group Scheen AJ et al. Lancet. 2006;368:

RIO-North America: Study design N = 3045 BMI ≥30 kg/m 2 or >27 kg/m 2 with comorbidity Year 1 Rimonabant 20 mg Enrolled = 1222 Completed = 673 Year 1 Placebo Enrolled = 607 Completed = 309 Pi-Sunyer FX et al. JAMA. 2006;295: Year 2 Placebo Enrolled = 327 Completed = 225 Year 2 Rimonabant 20 mg Enrolled = 333 Completed = 257 Year 2 Placebo Enrolled = 299 Completed = 214 Primary endpoints: Weight change from baseline; prevention of weight regain* Secondary endpoints: Weight loss ≥5% or ≥10%, waist circumference, lipids, MetS, BP, FG, fasting insulin, HOMA-IR *LOCF

RIO-North America: Weight change by treatment assignment Pi-Sunyer FX et al. JAMA. 2006;295: Intent-to-treat population Δ Body weight (kg) Weeks Year 1Year PlaceboRimonabant 20 mg Rimonabant 20 mg/PlaceboRimonabant 20 mg/Rimonabant 20 mg Placebo/Placebo

RIO-North America: Waist circumference by treatment assignment Pi-Sunyer FX et al. JAMA. 2006;295: Δ WC (cm) Weeks Year 1Year PlaceboRimonabant 20 mg Rimonabant 20 mg/PlaceboRimonabant 20 mg/Rimonabant 20 mg Placebo/Placebo

RIO-North America: Treatment effect on lipids at 1 year Pi-Sunyer FX et al. JAMA. 2006;295: No significant effect on LDL-C or total-C PlaceboRimonabant 20 mg ∆ HDL-C (mg/dL) Weeks ∆ TG (mg/dL)

Change (%) RIO-North America: Weight-independent and weight-dependent effects on lipids Pi-Sunyer FX et al. JAMA. 2006;295: HDL-C TG 42% Weight-dependent effect 58% Weight-independent effect 53% Weight-dependent effect 47% Weight-independent effect Rimonabant 20 mg vs placebo ANCOVA

RIO-North America: Weight-independent and weight-dependent effects on insulin and IR Δ (  U/mL) 50% Weight- dependent 50% Weight- independent Δ 49% Weight- dependent 51% Weight- independent Pi-Sunyer FX et al. JAMA. 2006;295: Rimonabant 20 mg vs placebo ANCOVA

RIO-North America: Adverse events Placebo (%) (n = 498) Rimonabant 20 mg (%) (n = 1042) URTI Nasopharyngitis Nausea Arthralgia Sinusitis Headache Back pain Influenza Diarrhea Viral gastroenteritis ≥5% incidence in any group Pi-Sunyer FX et al. JAMA. 2006;295:

RIO-North America: Adverse events, cont’d Placebo (%) (n = 498) Rimonabant 20 mg (%) (n = 1042) Dizziness Anxiety Bronchitis Depressed mood Fatigue Insomnia ≥5% incidence in any group Pi-Sunyer FX et al. JAMA. 2006;295:

Obesity program* depression-related events: Overall incidences Depressed mood disorders and disturbances Mood alterations with depressive symptoms Depressive disorders Placebo N = 2472 (%) 5 mg N = 2520 (%) 20 mg N = 2742 (%) Rimonabant *Obesity program (RIO-Europe, RIO-North America, RIO-Lipids, RIO-Diabetes, REBA, EFC5745 and ACT3801) Taking into account any patient exposure Data on file from sanofi-aventis.

Completed phase 2 and 3 studies* as of March 2007: All suicidality-related events Definitely suicidal (suicidal behavior/ideation) Possibly suicidal Rimonabant *Phase 2 studies: ACT4389, DRI3388, ACT4855, Metatrial study (DFI3077, DFI3024, DFI3067, DFI3138), PDY3796, DRI5747 and Phase 3 studies: RIO-Europe, RIO-North America, RIO-Lipids, RIO-Diabetes, REBA, SERENADE, EFC5745, ACT3801 and EFC4474, EFC4796, EFC4964, EFC5794, EFC4798 † Originally reported as a completed suicide but adjudicated as not enough information, fatal Using first randomized treatment 21 2 Placebo N = 3411 N (%) 11 1 † 5 mg N = 5254 N (%) mg N = 198 N (%) mg N = 7851 N (%) mg N = 206 N (%) (0.62) (0.06) (0.21) (0.02) (0) (0.61) (0.06) (0) Data on file from sanofi-aventis.

Rimonabant clinical safety: Summary Safety assessment based on extensive exposure up to 2 years The most frequent adverse events that led to drug discontinuation were depression, mood alteration, nausea and anxiety Psychiatric events: –Increased incidence of depression-related events and anxiety with rimonabant vs placebo, overall incidence remained relatively low –Most adverse events were mild to moderate intensity –Similar qualitative characteristics between rimonabant 20 mg vs placebo No clinical changes in laboratory test, electrocardiogram, or vital signs Long-term exposure did not identify new or increased risks and supports its long term administration in overweight/obese patients with at least one cardiometabolic risk factor Data on file from sanofi-aventis.

ACOMPLIA: European product information Therapeutic indication As an adjunct to diet and exercise for treatment of patients with BMI ≥30 kg/m 2 or >27 kg/m 2 with associated risk factors such as T2DM or dyslipidemia Adult dosing 20 mg daily, to be taken in the morning before breakfast No dosage adjustment in elderly, mild/moderate hepatic insufficiency, or mild/moderate renal impairment European Medicines Agency (EMEA).

ACOMPLIA: European product information, cont’d Contraindicated/Not recommended Pregnant or breast-feeding women Children below age 18 years Uncontrolled serious psychiatric illness such as major depression Taking antidepressant medication Severe renal or hepatic impairment Use with caution Receiving potent CYP3A4 inhibitors –Ketoconazole –Itraconazole –Ritonavir –Telithromycin –Clarithromycin –Nefazodone Treated for epilepsy Moderate hepatic impairment Age >75 years EMEA.